Arcellx, Inc.: management transactions · United States · SEC (Form 4)

About Arcellx, Inc.

Arcellx, Inc. (NASDAQ: ACLX) is a U.S.-listed biotechnology company focused on cell therapy, primarily for oncology. Founded in December 2014, the company was established to bring more control and adaptability to the promise of cell therapy. Its corporate headquarters are in Redwood City, California, in the United States, and its business model is that of a clinical-stage biotech, meaning value creation is still heavily tied to clinical milestones, regulatory approvals, and strategic partnerships. ([arcellx.com](https://www.arcellx.com/company/?utm_source=openai)) Arcellx’s platform is built around its proprietary D-Domain technology, which underpins two main technology families: ddCAR and ARC-SparX. The company describes its mission as engineering cell therapies that are safer, more effective, and more broadly accessible. Its lead program is anitocabtagene autoleucel, or anito-cel, an autologous BCMA-targeted cell therapy candidate in relapsed/refractory multiple myeloma. Arcellx has also advanced earlier programs such as CART-ddBCMA and ACLX-001, the first ARC-SparX program to enter clinical development. ([arcellx.com](https://www.arcellx.com/company/?utm_source=openai)) From a competitive standpoint, Arcellx operates in a highly capital-intensive and crowded field, competing against established cell-therapy developers and large pharma companies with deeper manufacturing, regulatory, and commercial resources. Its differentiation lies in its proprietary binder and platform design, which the company believes can deliver better control and potentially improved safety and efficacy. That positioning matters in multiple myeloma, where patients often receive several prior lines of therapy and treatment options can remain limited. Arcellx’s global strategic collaboration with Kite, a Gilead company, is an important industrial endorsement and potentially expands the long-term commercial path for anito-cel. ([arcellx.com](https://www.arcellx.com/company/?utm_source=openai)) Recent developments have remained centered on anito-cel and the company’s myeloma franchise. In 2025, Arcellx reported new positive data from its pivotal Phase 2 iMMagine-1 study, presented at ASH, supporting the program’s clinical narrative. The company’s 2024 Form 10-K also notes that Kite initiated a global randomized Phase 3 study, iMMagine-3, in second- through fourth-line relapsed/refractory multiple myeloma. In early 2026, Arcellx’s website highlighted additional Tandem meeting presentations and messaging around early CAR T access. For investors, the key takeaway is that Arcellx remains a high-upside NASDAQ biotech in the United States, with a lead asset that has advanced meaningfully, but with the usual clinical, regulatory, and execution risks inherent to late-stage cell therapy development. ([arcellx.com](https://www.arcellx.com/wp-content/uploads/2025/12/12.6.25_Arcellx_iMMagine_1_ASH-Data.pdf?utm_source=openai))